Adicet Bio Appoints Nick Harvey as Chief Financial Officer
16 sept. 2020 07h00 HE
|
Adicet Bio, Inc.
MENLO PARK, Calif. and BOSTON, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for...
Adicet Bio to Present at the Cantor Virtual Global Healthcare Conference
15 sept. 2020 16h10 HE
|
Adicet Bio, Inc.
MENLO PARK, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and...
Adicet Announces Completion of Merger with resTORbio
15 sept. 2020 08h55 HE
|
resTORbio, Inc.
- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology - -Trading to Commence on September 16, 2020 on The Nasdaq Global Market Under Ticker Symbol “ACET”- ...
resTORbio Provides Corporate Update and Reports Second Quarter 2020 Financial Results
30 juil. 2020 07h30 HE
|
resTORbio, Inc.
BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio Announces an Award from the National Institute on Aging to Fund a Pilot Study of RTB101 as COVID-19 Prophylaxis in Older Adults
28 juil. 2020 07h00 HE
|
resTORbio, Inc.
BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- resTORbio resTORbio, Inc. (Nasdaq: TORC) today announced the award from the National Institute on Aging to fund a randomized, double-blind,...
resTORbio Announces Initiation of Study to Evaluate if Antiviral Prophylaxis with RTB101 Reduces the Severity of COVID-19 in Nursing Home Residents
28 mai 2020 07h00 HE
|
resTORbio, Inc.
BOSTON, May 28, 2020 (GLOBE NEWSWIRE) -- resTORbio (Nasdaq: TORC) today announced the initiation of a randomized, double-blind, placebo-controlled trial of RTB101, an investigational...
resTORbio Provides Corporate Update and Reports First Quarter 2020 Financial Results
07 mai 2020 07h30 HE
|
resTORbio, Inc.
BOSTON, May 07, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or...
resTORbio to Host its 2020 Annual Shareholder Meeting Virtually on June 3, 2020
30 avr. 2020 16h01 HE
|
resTORbio, Inc.
BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC) today announced that due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being...
resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology
29 avr. 2020 07h00 HE
|
resTORbio, Inc.
Combined Company to Focus on Adicet’s Technology and Continue Operations as “Adicet Bio” Adicet’s lead asset ADI-001 is an allogeneic gamma delta T cell therapy expressing a chimeric antigen receptor...
resTORbio Announces Delay of its Ongoing Phase 1b/2a trial of RTB101 in Patients with Parkinson’s Disease Due to COVID-19 Level 4 Alert in New Zealand
03 avr. 2020 08h00 HE
|
resTORbio, Inc.
BOSTON, April 03, 2020 (GLOBE NEWSWIRE) -- resTORbio (Nasdaq: TORC) today announced that it will postpone enrollment in the fifth cohort of its ongoing Phase 1b/2a trial of RTB101, an orally...